Encysive To Cut U.S. Work Force By 70 Percent To Curb Cash Flow
This article was originally published in The Pink Sheet Daily
Executive Summary
Company also appoints George Cole to CEO, replacing Bruce Given, following on the heels of an FDA “approvable” letter for Thelin.
You may also be interested in...
Encysive To Enter Dispute Resolution With FDA Over Third Thelin “Approvable” Letter
Company asserts that FDA’s data analysis of STRIDE-2 trial for Thelin does not follow special protocol assessment agreement.
Thelin's Third "Approvable" Letter Recommends Additional Clinical Trial
Encysive may be forced to make "significant reductions" to infrastructure and workforce, firm says June 15.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.